AGU carrier status, and the founder variant no consumer chip looks for
A single change in a single gene explains almost every case of aspartylglucosaminuria in Finland. That makes it about the simplest carrier test genetics has to offer, and it appears on none of the consumer chip products Finnish customers actually buy.
Also known as: AGA carrier, aspartylglucosaminidase deficiency, AGU-Fin.
- Gene
- AGA
- Inheritance
- Autosomal recessive
- Carrier frequency
- roughly 1 in 60 in Finland, concentrated in the eastern and northern founder regions; very rare elsewhere in the world
What it is
Aspartylglucosaminuria is a recessive lysosomal storage condition caused by changes in AGA, the gene for an enzyme that breaks a specific chemical link during the routine recycling of glycoproteins. When the enzyme is missing, the partly dismantled fragments accumulate inside lysosomes throughout the body, including in the brain. GeneReviews puts the Finnish incidence at between 1.5 and 5 per 100,000 live births and records roughly 500 people identified worldwide with disease-causing changes in both copies of the gene. Those two numbers together are the shape of the condition: uncommon in Finland, and close to absent everywhere else.
The course is slower than the phrase "storage disease" tends to suggest. Children reach their early milestones with what GeneReviews describes as mild to moderate delay, then acquisition of new skills plateaus somewhere between late childhood and early adolescence, and adults undergo progressive psychomotor decline. The early years give comparatively little away, which is part of why the diagnosis is often arrived at well after the first signs.
There is no cure. Management is supportive, directed at the problems as they appear. Work on disease-modifying approaches is underway and GeneReviews lists haematopoietic stem cell transplant, pharmacological chaperones and AAV9 gene transfer among the therapies under investigation, which is a different statement from saying a treatment exists. It does not yet.
How it is inherited
Aspartylglucosaminuria is autosomal recessive. A carrier has one changed copy of AGA and one working copy, and the working copy makes enough enzyme. GeneReviews states the position without hedging: heterozygotes are asymptomatic and are not at risk of developing the disorder. What carrier status affects is family planning. If a reproductive partner also carries an AGA change, each pregnancy has a one in four chance of an affected child, which is why testing the partner is the step that actually resolves anything.
The reason a Finnish reader may meet this gene at all comes down to population history rather than to anything about them. Almost all Finnish AGU traces to one change, c.488G>C, replacing a cysteine at position 163 of the protein, and GeneReviews reports that this single variant accounts for 98% of pathogenic variants in the Finnish population. It is roughly fifty times commoner in Finns than in other Europeans. The 2022 review of the Finnish genetic heritage in Disease Models and Mechanisms describes why: regions of Finland were settled by founder populations of around twenty to forty families, and a variant that happened to be present in one of them was carried forward at a frequency it would never have reached in a larger, more mixed population. A carrier frequency of this kind is a fact about where a population came from, not a verdict on anybody's health.
What your raw DNA file can and cannot tell you
Start with the chip file, because this is the condition that shows most clearly what a consumer array is and is not for. 23andMe publishes the list of conditions its carrier status reports cover. Re-checked in August 2026 it runs to 46 conditions, and aspartylglucosaminuria is not one of them. So a Finnish customer holding a 23andMe export has never been told anything at all about AGA. Here is what makes that worth pointing at rather than shrugging about: this is not a technical limitation. One substitution at one position explains 98% of Finnish cases, and a single fixed substitution is precisely the kind of variant a genotyping array reads well and cheaply. The absence is a decision about which markets an array is designed for. An array sold worldwide spends its positions on variation that is common across many populations, and a variant fifty times enriched in Finns loses that competition. The technology could answer this question. It was not asked to.
Aimosti does not issue carrier status from a chip file either, for this gene or for any other, and we would rather say so than return a blank that reads like reassurance. What our carrier module reads is a whole-genome VCF or gVCF, and it looks across AGA rather than at one chosen position. That distinction still matters even when a single variant explains 98% of cases, because the remaining 2% is real, and it is exactly the fraction that a test built around one position will report as nothing found. A negative result from a single-position test and a negative result from reading the gene are different claims, and only the second one has looked where the rarer changes live.
This product is not clinical carrier screening. Our panel deliberately omits conditions a short-variant file cannot call, and a re-analysis of a file you already own is not a substitute for a validated, gene-targeted carrier test ordered through a clinic. What a re-analysis can do is tell you the question is worth asking. If you are making reproductive decisions, the useful next steps are testing a partner and speaking to a genetic counsellor, in that order, and neither of those is something software should be doing for you.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
Does 23andMe or AncestryDNA test for aspartylglucosaminuria?
23andMe's published carrier status list does not include aspartylglucosaminuria, so its reports say nothing about AGA. That is a notable gap for a Finnish customer, because AGU is one of the conditions the Finnish population carries at a meaningfully higher rate than other Europeans, and because a single common founder variant would be straightforward for an array to type. AncestryDNA does not offer carrier status reports at all. Neither product was built with this population in mind.
If one variant causes 98% of cases, why check anything beyond that one position?
Because of the other 2%. A test built around one position can only return two answers, and everything it was not designed to see is filed under the same heading as genuinely nothing found. That is a reasonable trade for a screening programme that knows its own limits and says so, and a poor one for somebody reading a consumer report and taking a blank at face value. Reading the whole gene costs more and answers a wider question, which is why our carrier module works from sequencing files rather than from chip positions.
I am an AGU carrier. Does it affect my health?
No. GeneReviews states that carriers are asymptomatic and not at risk of developing the disorder, and there is no ambiguity in the literature on this point. One working copy of AGA produces enough enzyme. Carrier status is information about what you might pass on, not about what will happen to you, and the practical consequence of it is deciding whether to have a reproductive partner tested.
Is there a treatment for AGU?
There is no cure and no approved disease-modifying therapy. Care is supportive and directed at the specific problems as they arise. GeneReviews notes several approaches under investigation, including haematopoietic stem cell transplant, pharmacological chaperones and gene transfer using an AAV9 vector, and it is worth being precise about what that means: these are research therapies, not options available in a clinic today. Anyone weighing this for a family member should be talking to a metabolic specialist rather than reading a summary.
Why is AGU so much more common in Finland?
Founder effects. Parts of Finland were settled by small founder populations, on the order of twenty to forty families according to the 2022 Disease Models and Mechanisms review of the Finnish genetic heritage, and later remained relatively isolated. A rare variant carried by one of those founding families ends up at a frequency in their descendants that it would never have reached in a large mixed population. The same history explains why Finland has an unusual set of rare recessive conditions and, at the same time, is missing some that are common elsewhere.